TScan Therapeutics is a startup based in the United States, 4 tracked investors.
TScan Therapeutics is a company founded in 2015 headquartered in the United States. Brouky records 4 investors associated with the company.
TScan Therapeutics develops anti-tumor T cell receptors (TCRs) by identifying their antigens through a genome-wide high-throughput platform, enabling new immuno-oncology treatments for patients not served by current cancer therapies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.